六组氨酸标签重组人细胞珠蛋白通过清除活性氧抑制肝纤维化
本研究探讨六组氨酸标签重组人细胞珠蛋白(His-CYGB)的抗纤维化作用。Cygb缺陷小鼠在胆汁淤积或脂肪性肝炎模型中肝损伤、纤维化和活性氧(ROS)形成显著加重,而过表达Cygb则减轻。His-CYGB在体外被肝星状细胞(HSC)内吞并抑制ROS生成,减少胶原和α-SMA表达;静脉注射可抑制TAA或DDC诱导的小鼠肝炎症、纤维化和氧化损伤,无不良反应。
要点
- His-CYGB通过清除ROS抑制HSC活化和胶原产生。
- 静脉注射His-CYGB可减轻小鼠肝纤维化和炎症且无毒性。
- 干扰素-β分泌部分介导His-CYGB的抗纤维化作用。
核心结论
- His-CYGB可能作为人慢性肝病的抗纤维化治疗候选。
研究设计与样本
- 使用Cygb缺陷和过表达小鼠在胆汁淤积或脂肪性肝炎模型中观察表型。
- 在体外培养HSC和TAA或DDC诱导的晚期肝硬化小鼠中评估His-CYGB功能。
主要发现
- Cygb缺陷小鼠肝损伤、纤维化和ROS形成显著加重,过表达Cygb则减轻。
- His-CYGB经网格蛋白介导内吞进入HSC内体,显著抑制ROS生成,减少胶原1α1和α-SMA表达。
- 静脉注射His-CYGB显著抑制TAA或DDC小鼠肝炎症、纤维化和氧化细胞损伤,无不良反应。
- RNA测序显示炎症和纤维化相关基因下调,抗氧化基因上调。
- 注射的His-CYGB主要定位于HSC而非巨噬细胞,在人源化肝脏嵌合小鼠中无毒性。
临床怎么用
- His-CYGB可能作为抗纤维化生物制剂开发,需进一步临床验证。
- 靶向HSC的ROS清除策略在慢性肝病治疗中具有潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Antifibrotic therapy remains an unmet medical need in human chronic liver disease. We report the antifibrotic properties of cytoglobin (CYGB), a respiratory protein expressed in hepatic stellate cells (HSCs), the main cell type involved in liver fibrosis. APPROACH AND RESULTS: Cygb-deficient mice that had bile duct ligation-induced liver cholestasis or choline-deficient amino acid-defined diet-induced steatohepatitis significantly exacerbated liver damage, fibrosis, and reactive oxygen species (ROS) formation. All of these manifestations were attenuated in Cygb-overexpressing mice. We produced hexa histidine-tagged recombinant human CYGB (His-CYGB), traced its biodistribution, and assessed its function in HSCs or in mice with advanced liver cirrhosis using thioacetamide (TAA) or 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC). In cultured HSCs, extracellular His-CYGB was endocytosed and accumulated in endosomes through a clathrin-mediated pathway. His-CYGB significantly impeded ROS formation spontaneously or in the presence of ROS inducers in HSCs, thus leading to the attenuation of collagen type 1 alpha 1 production and α-smooth muscle actin expression. Replacement the iron center of the heme group with cobalt nullified the effect of His-CYGB. In addition, His-CYGB induced interferon-β secretion by HSCs that partly contributed to its antifibrotic function. Momelotinib incompletely reversed the effect of His-CYGB. Intravenously injected His-CYGB markedly suppressed liver inflammation, fibrosis, and oxidative cell damage in mice administered TAA or DDC mice without adverse effects. RNA-sequencing analysis revealed the down-regulation of inflammation- and fibrosis-related genes and the up-regulation of antioxidant genes in both cell culture and liver tissues. The injected His-CYGB predominantly localized to HSCs but not to macrophages, suggesting specific targeting effects. His-CYGB exhibited no toxicity in chimeric mice with humanized livers. CONCLUSIONS: His-CYGB could have antifibrotic clinical applications for human chronic liver diseases.
引用
- Dat NQ, Thuy LTT, Hieu VN, et al. Hexa Histidine-Tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species. Hepatology. 2021. PMID: 33576020. doi:10.1002/hep.31752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。